Location:

Article ID: 708321

Yale Cancer Center researchers have identified a potential therapy that combines two types of molecularly targeted drugs to produce a synergistic effect against head and neck cancer.

Article ID: 707928

Tony Teixeira from Danbury, Connecticut had minimally invasive robotic surgery to remove a rare heart tumor.

Article ID: 707521

An 86-year old woman from Danbury, Connecticut had Transcatheter Aortic Valve Replacement (TAVR) to treat severe aortic stenosis. TAVR is a minimally invasive procedure that is a safe alternative for patients who are at intermediate to high risk of complications from open heart surgery.

Article ID: 707305

Norwalk Hospital same day total joint replacement surgery leaves patient highly active and pain-free

Article ID: 706423

Just as the scientific community was reaching a consensus on the dangerous reality of climate change, the partisan divide on climate change began to widen.

Article ID: 705690

In a new study by Yale Cancer Center (YCC), scientists suggest that as the number of clinical trials in cancer immunotherapy grows exponentially, some caution should be exercised as we continue to better understand the biology of these new therapeutic targets.

Article ID: 703627

When melanoma turns metastatic, it spreads to the brain in more than 40% of patients. Published today in the Journal of Clinical Oncology (JCO), a study by Yale Cancer Center researchers show a checkpoint inhibitor immunotherapy drug has meaningful benefit for these patients.

Article ID: 703518

Branding matters when it comes to choosing a hospital, according to a new novel study by Yale Cancer Center (YCC) researchers published in the journal Annals of Surgical Oncology.

Article ID: 703425

U.S. and European guidelines on treating Polycythemia Vera (PV), a potentially deadly blood cancer, call for two treatments for patients with high-risk disease: therapeutic phlebotomy and cytoreductive therapy with a drug called hydroxyurea (HU). HU is the most commonly used option, but evidence for HU treatment is limited and both treatments are underused. Now, researchers at Yale Cancer Center have documented reduced risk of death and incidence of blood clots in patients receiving those therapies.

Article ID: 703369

Antonio Omuro, M.D., has been appointed the new Chief of Neuro-Oncology and a Leader for the Brain Tumor Program at Yale Cancer Center (YCC) and Smilow Cancer Hospital.